MaxCyte, Inc. (MXCT): R&D Expense
$20.82M
Year ended 2025-12-31
$16.76M
Trailing 12 months to 2026-06-30
+2.2%
3-year compound annual growth
+3.3%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $20.82M | -6.3% | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | $22.23M | -6.7% | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | $23.82M | +22.1% | 2025-03-11, From 2023-01-01 |
| 2022-12-31 | $19.51M | +26.7% | 2024-03-12, From 2022-01-01 |
| 2021-12-31 | $15.41M | -13.1% | 2023-03-15, From 2021-01-01 |
| 2020-12-31 | $17.73M | +0.8% | 2022-03-22, From 2020-01-01 |
| 2019-12-31 | $17.59M | n/a | 2022-03-22, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $20.82M | -6.3% |
| OmniAb, Inc. (OABI) | 2025-12-31 | $47.75M | -13.3% |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | $182.5K | -41.6% |
| bioAffinity Technologies, Inc. (BIAF) | 2025-12-31 | $1.38M | -5.3% |
| Absci Corp (ABSI) | 2025-12-31 | $81.42M | +27.5% |
| iSpecimen Inc. (ISPC) | 2024-12-31 | $1.49M | -7.8% |
| OneMedNet Corp (ONMDW) | 2025-12-31 | $1.51M | +3.3% |
| Incyte Corp (INCY) | 2025-12-31 | $2.05B | -21.4% |
Compare MXCT, OABI, FOXO, BIAF side by side · Screen every company in Services-Commercial Physical & Biological Research ↗